Shilpa Medicare Limited Approves Final Dividend, Announces Office Shifts, and Strategic Investment

Shilpa Medicare Limited Approves Final Dividend, Announces Office Shifts, and Strategic Investment​

Shilpa Medicare Limited announced several key corporate actions following its Board meeting held on May 22, 2026. The Board reviewed and approved the audited financial statements for the year ended March 31, 2026, and recommended a final dividend.

The Board also outlined significant strategic shifts, including plans to shift the registered offices of the parent company and its wholly owned subsidiaries from Karnataka to the state of Maharashtra. Furthermore, subsidiaries Shilpa Pharma Lifesciences Limited, Shilpa Biologicals Pvt Ltd, and Shilpa Biocare Pvt Ltd are undertaking an equity investment of 28% in Neo Green Power Project Private Limited.

Financial Highlights and Dividend Recommendation​

The Board approved the following financial documentation:

• Audited standalone and consolidated financial statements for the financial year ended March 31, 2026.
• Audited standalone and consolidated financial results for the Fourth quarter and the full financial year ended March 31, 2026.
• A declaration confirming that the auditors provided an unmodified opinion on the audited financial statements for the year ended March 31, 2026.

In a major corporate decision, the Board recommended a final dividend of Re. 0.60/- (60%) per equity share of face value of Re. 1/- each for FY 2025-26. This dividend is subject to approval by the members at the ensuing Annual General Meeting.

Governance and Appointments​

The Board also addressed corporate governance matters by appointing new auditors for the fiscal year 2026-27:

• Cost Auditors: M/s. V.J.Talati & Co., Cost Accountants were appointed as Cost Auditors for FY 2026-27.
• Internal Auditors: M/s ANEJA ASS OCIATES were appointed as Internal Auditors for FY 2026-27.

Corporate Structure and Investments​

On the operational front, the company announced plans for a multi-state shift:

• Shilpa Medicare Limited: The company plans to shift its registered office from Karnataka to Maharashtra and to alter the situation clause of its memorandum of association, pending member approval.
• Subsidiaries: Shilpa Medicare Limited’s wholly owned subsidiaries, Shilpa Pharma Lifesciences Limited, Shilpa Biologicals Private Limited, Shilpa Biocare Private Limited, and Sampra Holdings Private Limited, are also undertaking a move from Karnataka to Maharashtra.

In a strategic move, the three subsidiaries listed above—Shilpa Pharma Lifesciences Limited, Shilpa Biologicals Pvt Ltd, and Shilpa Biocare Pvt Ltd—are making an equity investment of 28% in Neo Green Power Project Private Limited.

Financial Performance Snapshot (In Lakhs)​

The Group's financial results reflect the performance through March 31, 2026.

The table below summarizes the key figures from the Consolidated Statement of Cash Flow:


The Consolidated Balance Sheet (Amounts in Lakhs) shows the Group's asset and liability structure:

SHILPAMED Stock Price Movement​

Shares of Shilpa Medicare Limited are edging higher to ₹495.75 as of 3:22 PM today, surging 4.45% in live trading. The stock sees robust buying interest on 4.08 million shares, accelerating its ascent and touching its 52-week high of ₹518.55.